What is it about?

High plasma triglyceride (TG) is an independent risk factor for CVD. Fibrates lower TG-levels through PPARα agonism; however they have relatively low selectivity for PPARα and their efficacy is limited by side effects. This Phase 2 trials shows that pemafibrate —a selective PPARα modulator —is effective, safe, and well-tolerated for the reduction of TG in in statin-treated European patients with hypertriglyceridemia.

Featured Image

Read the Original

This page is a summary of: Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy, Diabetes Care, March 2022, American Diabetes Association,
DOI: 10.2337/dc21-1288.
You can read the full text:

Read

Contributors

Be the first to contribute to this page